Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen to acquire dyslipidaemia specialist Dezima Pharma

Amgen to acquire dyslipidaemia specialist Dezima Pharma

18th September 2015

Amgen has announced the acquisition of the privately-held Netherlands-based biotechnology company Dezima Pharma.

The firm is focused on developing innovative treatments for dyslipidaemia, with the acquisition expected to strengthen Amgen's position in the cardiovascular market.

Dezima's lead molecule is TA-8995, an oral, once-daily cholesteryl ester transfer protein inhibitor. In a phase IIb trial the drug was able to reduced low-density lipoprotein cholesterol by 45 to 48 percent compared to baseline.

Under the terms of the agreement, Amgen will pay $300 million (191.79 million pounds) in cash at closing and up to $1.25 billion in additional payments contingent on the achievement of certain development and sales milestones.

Robert Bradway, chairman and chief executive officer at Amgen, said: "Amgen is proud to be on the leading edge of an exciting new wave of treatments for cardiovascular disease, an illness impacting millions of people worldwide."

This comes after the firm announced a new partnership with Xencor to jointly develop novel therapeutics in the areas of cancer immunotherapy and inflammation earlier this week.ADNFCR-8000103-ID-801800800-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.